Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints Bayer’s Sandra Peterson as group worldwide chair

Will have responsibility for troubled consumer goods division

J&J - Sandra PetersonSandra Peterson is to leave her role as chair and CEO of Bayer CropScience to join Johnson & Johnson (J&J) as its group worldwide chair.

Joining J&J on December 1, 2012, Peterson will have responsibility for J&J's IT and global supply chain, as well as its troubled consumer division, which has been beset by recalls and quality control problems these past two years.

The appointment is the first major executive change at J&J since Alex Gorsky became CEO in April, 2012, and he gave his thoughts on what Peterson could bring to such a high profile role.

“Sandi Peterson is an experienced global leader known for her strategic thinking and proven track record in growing businesses,” he said.

“She brings 25 years of experience to her new role, which will draw on her expertise in building fully integrated global businesses, and focusing on growth.”

Peterson has held her current role at Bayer since 2010, having previously served as president and CEO of Bayer Medical Care and president of Bayer HealthCare AG's Diabetes Care Division.

Prior to joining Bayer in 2005, Peterson spent five years in leadership roles at Medco Health Solutions following a series of positions at Nabisco, Whirlpool Corporation and McKinsey & Company.

“With her experience and commitment, Sandi has made significant contributions to the strong business performance of Bayer CropScience in the past two years,” said Dr Marijn Dekkers, CEO of Bayer.

“However, we accept her decision to continue her career back in her home country of the US and wish her all the best for the future.”

18th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics